September 6, 2013
Daiichi Sankyo has announced the results from the multinational PIII Hokusai-VTE study of its anticoagulant edoxaban (brand name in Japan: Lixiana) in patients with acute symptomatic deep vein thrombosis (DVT)/pulmonary embolism (PE) for the treatment and prevention of recurrent symptomatic...read more